Exact Sciences CORP Form 4 insider transactions

Jacob A. Orville, EVP, GM, Screening at Exact Sciences Corp, reports acquisition and disposal of common stock and restricted stock units.

Kevin Conroy, CEO of Exact Sciences, reports transactions involving common stock and restricted stock units, including acquisitions and disposals for tax withholding.

Director D. Scott Coward reports the vesting of restricted stock units and subsequent tax withholding of shares.

EVP Jacob Orville reports transactions involving Exact Sciences Corp. common stock, including acquisitions from vesting of restricted stock units and performance share units, as well as disposals for tax withholding.

EVP and GM of Precision Oncology at Exact Sciences, Brian Baranick, reports acquisition and disposal of common stock related to vesting of restricted stock units and performance share units.

Sarah Condella, EVP of Human Resources at Exact Sciences, reports the acquisition and disposal of company stock and restricted stock units.

James Herriott, SVP, General Counsel & Secretary of Exact Sciences Corp, reports transactions involving common stock and restricted stock units, resulting in an adjusted beneficial ownership.

Kimberly J. Popovits, a director at Exact Sciences Corp, acquired 6,387 shares of common stock on January 2, 2025, as part of the company's non-employee director compensation policy.

Katherine S. Zanotti, a director at Exact Sciences, filed an amended Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

Daniel J. Levangie, a director at Exact Sciences, files an amendment to a previous Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

Shacey Petrovic, a director at Exact Sciences, filed an amended Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

Michael J. Barber, a director at Exact Sciences Corp, files an amendment to a previous Form 4 to correct the number of restricted stock shares awarded.

James Edward Doyle, a director at Exact Sciences Corp, filed an amendment to a previous Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

Paul J. Clancy, a director at Exact Sciences Corp, files an amendment to a previous Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

Kathleen Sebelius, a director at Exact Sciences Corp, files an amendment to a previous Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

D. Scott Coward, a director at Exact Sciences Corp, files an amended SEC Form 4 to correct the number of restricted stock shares awarded due to an administrative error.

Exact Sciences CEO Kevin Conroy purchased 19,500 shares of company stock for approximately $1 million, increasing his total holdings.

Brian Baranick, EVP and GM of Precision Oncology at Exact Sciences, sold 929 shares of common stock at $70 per share on October 8, 2024, under a pre-arranged 10b5-1 trading plan.

Brian Baranick, EVP and GM of Precision Oncology at Exact Sciences, reported the sale of 929 shares of common stock at $70 per share on September 18, 2024, according to a Form 4 filing.

Brian Baranick, EVP, GM, Precision Oncology at Exact Sciences Corp, reports the vesting of restricted stock units, tax withholding, and acquisition of new restricted stock units.

EVP and GM of Screening at Exact Sciences, Jacob Orville, reports acquisition of restricted stock units and holdings in common stock and a 401(k) plan.

Director James Edward Doyle acquired 5,444 shares of Exact Sciences Corp. common stock on June 13, 2024, as part of the company's non-employee director compensation policy.

Director Kathleen Sebelius reports acquiring 6,889 shares of Exact Sciences Corp. common stock on June 13, 2024, as part of the company's non-employee director compensation policy.

Director Paul J. Clancy reports acquiring 5,444 shares of Exact Sciences Corp. common stock on June 13, 2024, as part of the company's non-employee director compensation policy.

Katherine S. Zanotti, a director at Exact Sciences Corp, acquired 5,444 shares of common stock on June 13, 2024, as part of the company's non-employee director compensation policy.

Director Daniel J. Levangie reports acquiring 5,444 shares of Exact Sciences Corp. common stock on June 13, 2024, as part of the company's non-employee director compensation policy.

Director D. Scott Coward reports acquisition of 5,444 shares of Exact Sciences Corp. stock and indirect ownership of 4,693 shares held in a 401(k) plan.

Director Shacey Petrovic reports acquiring shares of Exact Sciences common stock as part of director compensation and disposing of shares held indirectly through an annuity trust.

Director Michael Barber of Exact Sciences Corp. reports the acquisition of 5,444 shares of restricted stock and 7,422 deferred stock units on June 13, 2024, as part of the company's non-employee director compensation policy.

Director D. Scott Coward reports acquisition and disposal of Exact Sciences Corp. stock related to performance share unit settlement and tax obligations.